<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210718051924N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-08-22</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>The effect of a course of exercise with garlic supplementation on some coagulation factors in middle-aged men with deep vein thrombosis</public_title>
      <acronym></acronym>
      <scientific_title>The effect of a six-month combined care program with garlic supplementation on coagulation factors (INR, PTT, PT), Fibrinogen and platelets in middle-aged men with deep vein thrombosis (DVT)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-07-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57569</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: First, using the library, field and laboratory methods, measures were taken to collect information about the intervention. After identifying individuals with deep vein thrombosis (DVT) and selecting the research sample, the participants' consent to complete the study was completed. After obtaining the consent to participate in the research, the samples were randomly divided into 4 groups of 10 people: Group 1: Resistance (who performed the designed combined exercises) 2: Garlic consumption group (who consumed garlic according to the plan) 3: Combined exercise with garlic (who did the designed combined exercises and also consumed garlic) 4: Control (did not participate in any of the sports activities) Group 1, 8 weeks, did 3 sessions of combined exercise every week. All exercise programs, starting with the principle of overload, increasingly started from the first week and continued until the end of the eighth week. The experiments were performed in two stages, one day before the first training session (pre-test) and 48 hours after the last training session (post-test) in the eighth week of training, after 10 to 12 hours of fasting. It should be noted that all subjects, in addition to the intervention, continued to take warfarin tablets to the extent prescribed by the doctor for each person during the treatment period, and the amount and timing was determined by each person's doctor. The combined exercise program was performed for 24 weeks with a frequency of 3 days a week, combining aerobic and resistance exercises. Weight movements in 2 sets and 10 to 12 repetitions will include chest press, wire pull side pull, boat pull, leg press and bending and opening the thigh. Exercises started with 40% of a maximum repetition and lasted 22 minutes. In the aerobic section, the subjects trained for 22 minutes with an intensity of 40% of maximum heart rate (HRmax). At 4 weeks the intensity of the exercises was re-evaluated. At the beginning of the sessions they had 3 to 5 minutes of warm-up time and at the end of 3 to 5 minutes they had time to cool down, Blinding description: Both the researcher and the participants.</study_design>
      <phase>3</phase>
      <hc_freetext>Deep vein thrombosis (DVT).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Combined exercise (resistance training + aerobic exercise):  The combined exercise program was performed for 24 weeks with a frequency of 3 days a week, combining aerobic and resistance exercises. Weight movements in 2 sets and 10 to 12 repetitions will include chest press, wire pull side pull, boat pull, leg press and bending and opening the thigh. Exercises started with 40% of a maximum repetition and lasted 22 minutes. In the aerobic section, the subjects trained for 22 minutes with an intensity of 40% of maximum heart rate (HRmax). At 4 weeks the intensity of the exercises was re-evaluated. At the beginning of the sessions they had 3 to 5 minutes of warm-up time and at the end of 3 to 5 minutes they had time to cool down. Intervention 2: Intervention group 2: Use of garlic supplement: Garlic supplement consumption in the present study was 1200 mg daily as one capsule per day and in the control group placebo (1200 mg of starch) was used. The garlic extract was prepared from the American Nature Company with a health license from the General Directorate of Food Supervision of the Ministry of Health. Intervention 3: Intervention group 3: Combined exercise (resistance training + aerobic exercise):  The combined exercise program was performed for 24 weeks with a frequency of 3 days a week, combining aerobic and resistance exercises. Weight movements in 2 sets and 10 to 12 repetitions will include chest press, wire pull side pull, boat pull, leg press and bending and opening the thigh. Exercises started with 40% of a maximum repetition and lasted 22 minutes. In the aerobic section, the subjects trained for 22 minutes with an intensity of 40% of maximum heart rate (HRmax). At 4 weeks the intensity of the exercises was re-evaluated. At the beginning of the sessions they had 3 to 5 minutes of warm-up time and at the end of 3 to 5 minutes they had time to cool down. Garlic supplement consumption in the present study was 1200 mg daily as one capsule per day and in the control group placebo (1200 mg of starch) was used. The garlic extract was prepared from the American Nature Company with a health license from the General Directorate of Food Supervision of the Ministry of Health.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After the study, I will make the result transparently available for publication in the Islamic Azad University, Kermanshah Branch.

When:
After the end of the study in early August 2016

To whom:
Islamic Azad University, Kermanshah Branch

Conditions:
To inform patients of deep vein thrombosis treated with warfarin about the risk of blood clots or leg bleeding regarding recovery after using one of these study methods

Where to obtain:
Hamed Saed

How to obtain:
The request must be in writing and from the Islamic Azad University of Kermanshah

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamed Saed</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 24, Shahid Khanmohammadi Fourth Alley, 18 meters from the first street, Jihad Town, Kermanshah</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6715788638</zip>
        <telephone>+98 83 3432 8035</telephone>
        <email>hamedsaed1@yahoo.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hamed Saed</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 24, Shahid Khanmohammadi Fourth Alley, 18 meters from the first street, Jihad Town, Kermanshah</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6715788638</zip>
        <telephone>+98 83 3432 8035</telephone>
        <email>hamedsaed1@yahoo.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Middle-aged men 40 to 60 years old with deep vein thrombosis (DVT) in Kermanshah</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>60 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I82.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute embolism and thrombosis of deep veins of lower extremity</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Combined exercise (resistance training + aerobic exercise):  The combined exercise program was performed for 24 weeks with a frequency of 3 days a week, combining aerobic and resistance exercises. Weight movements in 2 sets and 10 to 12 repetitions will include chest press, wire pull side pull, boat pull, leg press and bending and opening the thigh. Exercises started with 40% of a maximum repetition and lasted 22 minutes. In the aerobic section, the subjects trained for 22 minutes with an intensity of 40% of maximum heart rate (HRmax). At 4 weeks the intensity of the exercises was re-evaluated. At the beginning of the sessions they had 3 to 5 minutes of warm-up time and at the end of 3 to 5 minutes they had time to cool down.</i_keyword>
      <i_keyword>Intervention group 2: Use of garlic supplement: Garlic supplement consumption in the present study was 1200 mg daily as one capsule per day and in the control group placebo (1200 mg of starch) was used. The garlic extract was prepared from the American Nature Company with a health license from the General Directorate of Food Supervision of the Ministry of Health.</i_keyword>
      <i_keyword>Intervention group 3: Combined exercise (resistance training + aerobic exercise):  The combined exercise program was performed for 24 weeks with a frequency of 3 days a week, combining aerobic and resistance exercises. Weight movements in 2 sets and 10 to 12 repetitions will include chest press, wire pull side pull, boat pull, leg press and bending and opening the thigh. Exercises started with 40% of a maximum repetition and lasted 22 minutes. In the aerobic section, the subjects trained for 22 minutes with an intensity of 40% of maximum heart rate (HRmax). At 4 weeks the intensity of the exercises was re-evaluated. At the beginning of the sessions they had 3 to 5 minutes of warm-up time and at the end of 3 to 5 minutes they had time to cool down. Garlic supplement consumption in the present study was 1200 mg daily as one capsule per day and in the control group placebo (1200 mg of starch) was used. The garlic extract was prepared from the American Nature Company with a health license from the General Directorate of Food Supervision of the Ministry of Health.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Prothrombin Time (PT)Partial Thromboplastin Time (PTT)International Normalization Ratio (INR), Fibrinogen, platelets. Timepoint: 24 hours before the start of the study and 48 hours after the last training session after 24 weeks. Method of measurement: It was measured by class coagulation method with laboratory kits (ACL) and fully automatic device (ACL 8000 made in Italy).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-12-22</approval_date>
        <contact_name>Kermanshah University of Medical Sciences</contact_name>
        <contact_address>Kermanshah University of Medical Sciences Kermanshah Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
